Efficacy of Fixed-doses of Antihypertensive and Statin Drugs

Inclusion Criteria: * Participants of both sexes aged between 18 and 65 years; * Participants diagnosed with uncontrolled hypertension (stage 1), according VII Brazilian Guideline of Hypertension; * Participants diagnosed with dyslipidemia, according to the V Brazilian Guidelines on Dyslipidemia and Prevention of Atherosclerosis; * Signed consent. Exclusion Criteria: * Participants with a previous diagnosis of familial hypercholesterolemia (homozygous); * Concomitant use of angiotensin II receptor blocker (ARB) or inhibitor of angiotensin converting enzyme (ACE); * Participants with total cholesterol (TC) above 500 mg / dL or triglyceride (TG) above 500 mg / dL; * Participants with hypertension (stage 2 or 3) according VII Brazilian Guideline of Hypertension; * History of congestive heart failure (CHF) functional class III or IV (NYHA);; * Any clinical, laboratory and electrocardiographic that, in the judgment of the investigator, may interfere with the safety of research participants; * Creatine phosphokinase (CPK) levels above the established laboratory normal range; * Transaminases (ALT and ASL) serum above 2 times the established laboratory normal range; * Body mass index (BMI) ≥35 kg / m²; * Immunocompromised participants (eg.: malignancies, patients with Acquired Immunodeficiency Syndrome etc); * Chronic use of drugs that may interact with the drugs of the study; * History hypersensitivity to the active ingredients used in the study; * Pregnancy or risk of pregnancy and lactating patients; * History of alcohol abuse or illicit drug use; * Participation in clinical trial in the year prior to this study.